Bausch and Lomb unveils new logo
ROCHESTER, N.Y. Global eye health company Bausch and Lomb unveiled its redesigned company logo and icon. Both incorporate hues of the company’s traditional blue and green colors, while introducing the plus (+) symbol to represent the organization’s strong commitment to innovation and partnership with practitioners as a leader in eye health.
“Our new corporate identity reflects the ongoing evolution of Bausch + Lomb as we make strides in growing our business for the benefit of medical practitioners, retail partners, consumers and patients around the world,” said Gerald M. Ostrov, the company’s chairman and CEO. “Based on our strong momentum coming out of last year, as well as a number of planned new product launches and market initiatives over the coming months, we believe that 2010 will be a banner year for the company and the millions of people we’re so fortunate to serve each year.”
The new logo and B+L icon will be phased in by Bausch + Lomb over time, co-existing with the former “pathways” logo for the next 18 to 24 months as product packaging and other materials are updated.
FDA, health organizations to study safety of medications taken during pregnancy
SILVER SPRING, Md. A new research program called the Medication Exposure in Pregnancy Risk Evaluation will fund research to study the effects of prescription medications used during pregnancy, the Food and Drug Administration announced last week.
The program is a collaboration among FDA and researchers at the HMO Research Network Center for Education and Research in Therapeutics, Kaiser Permanente’s multiple research centers and Vanderbilt University.
About two-thirds of women who deliver a baby have taken at least one prescription medication during pregnancy according to a journal article published in the American Journal of Obstetrics and Gynecology. There are very few clinical trials that test the safety of medications in pregnancy due to concerns about the health of the mother and child.
“This program is a great example of FDA and the private sector working together to improve the health of pregnant women and their children,” stated Margaret Hamburg, FDA commissioner. “These data will guide regulatory policy and influence medical practice.”
To overcome the challenges presented by the lack of clinical trial data about the use of medications during pregnancy, the research program will link healthcare information for mothers and their babies in each of the participating research sites. Collectively, the 11 participating sites have healthcare information for about 1 million births over the past seven years (2001-2007). Many of the mothers associated with these births likely used medication during their pregnancies and now, with the program in place, the FDA and participating researchers have a systematic and timely way of retrieving information from this network.
“This collaborative effort creates a unique resource to study the effects of medication in pregnant women and their children,” stated Gerald Dal Pan, director of the Office of Surveillance and Epidemiology at the FDA’s Center for Drug Evaluation and Research. “Results of these studies will provide valuable information for patients and physicians when making decisions about medication during pregnancy.”
Nutrition 21 completes sale of direct response, retail businesses to Nature’s Products
PURCHASE, N.Y. Nutrition 21 on Tuesday announced that it has sold substantially all of the assets of its direct response and retail businesses to Nature’s Products, based in Sunrise, Fla. The purchase price was approximately $3.2 million, plus the assumption of designated liabilities.
“We entered into this transaction to focus our limited financial resources on our profitable ingredients business,” stated Michael Zeher, Nutrition 21 president and CEO.